A comparison of the impact of isotope ( 125I vs. 103Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer

Brachytherapy

Volumn 11, Issue 4, 2012, Pages 271-276

  Kollmeier, Marisa A ^a   Pei, Xin ^a   Algur, Ece ^a   Yamada, Yoshiya ^a   Cox, Brett W ^a   Cohen, Gil'ad N ^a   Zaider, Marco ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; External beam radiation therapy; Iodine 125; Palladium 103; Prostate cancer

Indexed keywords

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE DISTRIBUTION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; UROGENITAL TRACT DISEASE;

AGED; BRACHYTHERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEW YORK; PALLADIUM; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84862541928     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.11.002     Document Type: Article

References (22)

1. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
2. Zietman A.L., DeSilvio M.L., Koper P.C., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005, 294:1233-1239.
3. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
4. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
5. Zelefsky M.J., Kuban D.A., Levy D.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
6. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006, 66:416-423.
7. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
8. Peschel R.E., Colberg J.W., Chen Z., et al. Iodine 125 versus palladium 103 implants for prostate cancer: Clinical outcomes and complications. Cancer J 2004, 10:170-174.
9. Herstein A., Wallner K., Merrick G., et al. I-125 versus Pd-103 for low-risk prostate cancer: Long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J 2005, 11:385-389.
10. Wallner K., Merrick G., True L., et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 2003, 57:1297-1303.
11. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67:65-70.
12. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64:525-533.
13. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
14. Barry M.J., O'Leary M.P. Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am 1995, 22:299-307.
15. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998, 160:1379-1382.
16. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys 2002, 52:712-719.
17. Gelblum D.Y., Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48:119-124.
18. Kang S.K., Chou R.H., Dodge R.K., et al. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 53:99-103.
19. Albert M., Tempany C.M., Schultz D., et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 2003, 98:949-954.
20. Taira A.V., Merrick G.S., Galbreath R.W., et al. Erectile function durability following permanent prostate brachytherapy. Int J Oncol Biol Phys 2009, 75:639-648.
21. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007, 67:57-64.
22. Dattoli M., Wallner K., True L., et al. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol 2010, [Epub ahead of print].